At a glance
- Originator Aventis
- Class Antihyperlipidaemics; Cyclohexylamines; Small molecules
- Mechanism of Action Squalene synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 03 Jul 2002 No development reported - Preclinical for Hyperlipidaemia in USA (unspecified route)
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 20 Mar 1996 Preclinical development for Hyperlipidaemia in United Kingdom (Unknown route)